What does MindMaze Therapeutics do?

MindMaze Therapeutics is a Swiss-based, commercial-stage company that develops and commercialises digital treatments for neurological diseases and brain disorders. Its platform integrates software, sensors and telehealth, with solutions deployed across clinics and home settings.

Where are MindMaze Therapeutics’ solutions currently deployed?

MindMaze Therapeutics said its solutions are deployed across more than 100 hospitals and neurorehabilitation facilities in Europe, including leading academic centres. The company also operates across clinic and home settings globally, according to the update.

Which neurological conditions does MindMaze Therapeutics address?

MindMaze Therapeutics said its neurotherapeutics address conditions including stroke, Parkinson’s disease and at-risk ageing. The company is also expanding its research and development pipeline into multiple sclerosis, spinal cord injury, traumatic brain injury and Alzheimer’s disease.

What is MindMaze Therapeutics doing to expand in the United States?

MindMaze Therapeutics is engaging with selected US-wide provider groups and commercial partners to broaden adoption of its platform. The company is also strengthening its US-based commercial organisation through recruitment efforts for field specialists and by consolidating medico-economic evidence.

Is MindMaze Therapeutics close to finalising a US commercial agreement?

MindMaze Therapeutics said it is working towards the potential finalisation of an agreement in the near term with selected US-wide provider groups and commercial partners. The update describes this as an ongoing process rather than a completed agreement.

What evidence is MindMaze Therapeutics developing for its US commercial expansion?

MindMaze Therapeutics is continuing to consolidate medico-economic evidence on clinical outcomes and cost efficiency across neurological indications. The company also referred to anticipated clinical readouts from ongoing studies at Vibra Healthcare hospitals and Mount Sinai Hospital.

What European reimbursement initiatives is MindMaze Therapeutics advancing?

MindMaze Therapeutics is advancing reimbursement-focused clinical initiatives in Europe to demonstrate the clinical and socio-economic benefits of its integrated neurotherapeutic platform compared with standard models of care. The company said these initiatives are intended to support broader reimbursement and market access across European markets.

When are MindMaze Therapeutics’ SwissNeuroRehab and React-AVC studies expected to start?

MindMaze Therapeutics said the SwissNeuroRehab and React-AVC studies are planned to begin in the coming weeks. The company described the studies as part of its European reimbursement-focused clinical initiatives.

What organisational changes is MindMaze Therapeutics making after its business combination?

MindMaze Therapeutics has defined a structured integration plan following completion of its business combination, covering its organisation and portfolio. For selected non-core assets outside neurology, the company is evaluating strategic alternatives including potential outlicensing or disposal.

Which MindMaze Therapeutics directors have stepped down from the board?

Gregory Van Beek and Michael Stünkel have stepped down from MindMaze Therapeutics’ Board of Directors. The company said proposals for successor directors will be submitted at the next annual general meeting of shareholders.

What did MindMaze Therapeutics’ CEO say about the company’s outlook for 2026?

Chief Executive Officer Alexandre Capet said MindMaze Therapeutics is focused on expanding access to evidence-based neurotherapies, executing its roadmap and delivering clinical benefits to patients. He said the company’s operational momentum positions it to deliver continued meaningful progress throughout 2026.

Where do MindMaze Therapeutics shares trade and what is the ticker symbol?

MindMaze Therapeutics is listed on the SIX Swiss Exchange under the ticker MMTX.

What information is included in MindMaze Therapeutics’ March 2026 investor presentation?

MindMaze Therapeutics said its March 2026 investor presentation includes additional information about its business strategy, liquidity position and certain pro forma 2025 financial information. The presentation is available on the company’s website.

Home
News Intelligence
MindMaze Therapeutics Holding SA
MindMaze Therapeutics outlines post-listing plans and publishes March 2026 presentation

Back to all MindMaze Therapeutics Holding SA press releases

MindMaze Therapeutics Holding SA

OTCQB:MMTZF
SIX:MMTX

MindMaze Therapeutics outlines post-listing plans and publishes March 2026 presentation

Published Tuesday, 03 March 2026, 06:00 AM

Get alerts

Plain English summaries when MindMaze Therapeutics Holding SA announces news.

At a glance

Company: MindMaze Therapeutics Holding SA
Listings: OTCQB:MMTZF, SIX:MMTX
Announcement type: Corporate update
Published: Tuesday, 03 March 2026, 06:00 AM
Source announcement: eqs-news.com

FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices

Announcement Summary

MindMaze Therapeutics Holding SA (SIX: MMTX) provided a post-listing corporate update covering commercial expansion, European market access, organizational focus and governance.

The Company published its March 2026 investor presentation on March 3, 2026, covering strategy, liquidity and certain pro forma 2025 financial information.
The Company is discussing a potential agreement with selected U.S.-wide provider groups and commercial partners; finalization may occur in the near term.
The Company plans to initiate SwissNeuroRehab and React-AVC studies in Europe in the coming weeks to demonstrate benefits and support broader reimbursement.
Following completion of its business combination, the Company is evaluating alternatives for selected non-core assets outside neurology, including potential outlicensing or disposal.

Gregory Van Beek and Michael Stünkel stepped down from the Board; successor-director election proposals will be submitted at the next annual general meeting.

Investor FAQs

MindMaze Therapeutics provided a post-listing corporate update and published its March 2026 investor presentation on March 3, 2026. The update covered its United States commercial expansion, European market-access initiatives, organisational integration and governance.

Source announcement

Company: MindMaze Therapeutics Holding SA
Title: MindMaze Therapeutics Provides Corporate Update and Publishes March 2026 Investor Presentation
Published: Tuesday, 03 March 2026, 06:00 AM
Source site: eqs-news.com

Read the source announcement on eqs-news.com

FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.

Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.

Read the original press release

Full text as published, unedited.

Loading the original release…

Important Notice And Disclaimer

This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.

The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Ask about this announcement

Answers drawn only from this announcement

Reading the announcement…